If you have recently been diagnosed with glioblastoma multiforme (GBM) or know someone who has, you may want learn about a new study which is now recruiting patients.

ICT-107 Phase II Clinical Trial - FDA APPROVED

ImmunoCellular Therapeutics is conducting an FDA-approved, Phase II clinical trial designed to evaluate the safety and efficacy of an experimental cancer vaccine, ICT-107. To learn more about ICT-107, please click here.

You may be eligible for the clinical trial if you have recently undergone surgery to remove your tumor and you have not yet started treatment with radiation and chemotherapy.

If you would like us to send you more information
about this clinical trial, PLEASE FILL THE FORM BELOW
We will not share your name or contact information
with any outside parties — your privacy is important to us.